PTAB challenges

Proceedings overview

One AIA trial proceeding has been filed against US patent 10639404. This Inter Partes Review (IPR) is currently in the "Trial Instituted" stage, meaning the PTAB has agreed to review at least some of the challenged claims. This indicates that the patent is under active challenge, and its claims have not yet been hardened or invalidated through the PTAB process.

IPR2025-01042 — Solventum Corporation v. Wound Healing Technologies LLC

• Type: Inter Partes Review
• Filed: 2025-06-13
• Status: Trial Instituted. This means the PTAB has determined that there is a reasonable likelihood that at least one challenged claim is unpatentable, and a trial has been initiated to review those claims.
• Judge panel: Administrative Patent Judges Jennifer J. Chagnon, Brian F. McNamara, and Mark D. Ells.
• Petition grounds: Solventum Corporation challenged claims 1-20 of U.S. Patent No. 10,639,404 as unpatentable under 35 U.S.C. § 103 (obviousness) over various combinations of prior art, including U.S. Patent No. 6,106,499 (Adams), U.S. Patent App. Pub. No. 2004/0073200 (Zamierowski), and U.S. Patent No. 6,488,643 (Solomon).
• Institution decision: Instituted on 2026-04-23. The panel found that the Petitioner, Solventum Corporation, demonstrated a reasonable likelihood of prevailing in showing claims 1-20 are unpatentable under 35 U.S.C. § 103.
• Final Written Decision (if issued): Not yet issued. The trial was instituted on 2026-04-23, and a Final Written Decision is typically due within one year of institution.
• Settlement / termination: Not applicable; the proceeding is currently active.
• Appeal: Not applicable; a Final Written Decision has not yet been issued.
• Defensive value: This proceeding indicates that all claims (1-20) of US10639404 are currently under review by the PTAB for obviousness. If claims are ultimately canceled, any assertion of the patent relying on those claims would be significantly weakened. Conversely, if claims are sustained, it would strengthen the patent owner's position.

Strategic summary

All claims (1-20) of US10639404 are currently challenged in IPR2025-01042. As the status is "Trial Instituted," none of the claims have been canceled or sustained yet through a Final Written Decision. Therefore, all claims are still considered "untested" in terms of a final PTAB judgment. This means the patent owner's claims have been deemed sufficiently weak to warrant a full review, but their ultimate fate is pending.

The estoppel landscape for this patent is currently developing. Should IPR2025-01042 proceed to a Final Written Decision, Solventum Corporation (and its privies) would be estopped under § 315(e)(2) from asserting in other venues any ground raised or that reasonably could have been raised in this IPR against the instituted claims. For other potential defendants, however, the prior art grounds (primarily obviousness based on Adams, Zamierowski, and Solomon) remain available until a Final Written Decision is issued and becomes binding on the patent. The current proceeding, filed by Solventum Corporation, indicates an active defense by an operating company against the patent.

Recommended next steps

As IPR2025-01042 is in the "Trial Instituted" stage, the key milestone to watch is the issuance of the Final Written Decision, which is statutorily due approximately one year from the institution date of 2026-04-23. This means a decision can be anticipated around April 2027. Monitoring the PTAB E2E system for updates on IPR2025-01042 is crucial. The institution decision can be found on the USPTO PTAB Decisions portal.